Financial Data and Key Metrics Changes - In Q4 2025, the company reported revenues of $74.7 million, a 40% decline year-over-year, primarily due to a winding down of the seed business and reduced demand for crop inputs in Argentina [6][7][8] - For the full fiscal year, revenues totaled $335.3 million, down 28% year-over-year, with declines across all segments [8][12] - Adjusted EBITDA for Q4 was -$4.5 million, down from $19.9 million the previous year, largely due to a $22.7 million reduction in gross profit [13][15] - Full-year EBITDA was $28.3 million, down from $81.4 million in FY24, reflecting a $54.6 million decline in gross profit [15][18] Business Line Data and Key Metrics Changes - In the seed segment, revenues were $63.9 million for the year, a reduction of 34%, attributed to the transition to a royalty-based model [9][12] - Crop protection revenues for the full year were $181.9 million, down 20%, with a strong decline in Argentina offset by growth in bioprotection in the U.S. and adjuvants in Brazil [8][12] - Crop nutrition revenues were $89.5 million, down 37% year-over-year, driven by lower microbiota fertilizer sales in Argentina [8][12] Market Data and Key Metrics Changes - The company experienced a significant decline in sales in Argentina due to adverse on-farm economics and reduced spending on agricultural inputs [5][6] - International sales of core technologies grew, with adjuvant sales in Brazil almost doubling and bioprotection products in the U.S. growing nearly 40% [7][8] Company Strategy and Development Direction - The company is focusing on cash generation and improving working capital management, targeting a running rate of 5 to 6 months of sales [19][20] - Cost structure adjustments are being accelerated, with targeted operating expense savings of around 10% to 12% [19][20] - The company aims to scale up biological initiatives and support key partners in Latin America while onboarding new partnerships in the U.S. and Australia [21][22] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges faced in fiscal 2025, attributing them to a combination of macroeconomic shifts in Argentina and changes in the HB4 seed business strategy [4][5] - The company expects to improve EBITDA margins and progress towards a more robust balance sheet with a normalized agricultural input market in Argentina and continued growth in the U.S. and Brazil [20][22] Other Important Information - Total financial debt stood at $255.5 million, slightly lower than the previous quarter, reflecting repayments of unsecured public bonds and working capital loans [17][18] - Cash and cash equivalents totaled $34.6 million, resulting in a net financial debt of $220.8 million as of June 30, 2025 [18] Q&A Session Summary Question: What metrics should be focused on in the next six to nine months? - Management emphasized cash generation and profitability expansion as key metrics, with less priority on top-line growth under current circumstances [24][25] Question: Can you elaborate on cost savings initiatives? - Management indicated that cost savings of $3 to $3.5 million per quarter are expected, achieved through workforce streamlining and right-sizing capacities [29][31] Question: What was the gross profit from the Syngenta agreement in fiscal 2025? - Management clarified that the gross profit from Syngenta for the fiscal year was approximately $18 million, with no upfront payment recognized this year [34][36] Question: What is the outlook for the HB4 product? - Management highlighted a significant agreement with GDM to reposition HB4 technology for weed control, which is expected to generate revenues in the upcoming fiscal year [42][43] Question: How is the inventory situation in Argentina? - Management noted that inventory levels have been almost depleted, indicating a potential recovery in sales as planting needs arise [60][61]

Financial Data and Key Metrics Changes - In Q4 2025, the company reported revenues of $74.7 million, a 40% decline year-over-year, primarily due to the winding down of the seed business and reduced demand for crop inputs in Argentina [6][8][9] - For the full fiscal year, revenues totaled $335.3 million, down 28% year-over-year, with declines across all segments [8][12] - Adjusted EBITDA for Q4 was -$4.5 million, down from $19.9 million the previous year, largely due to a $22.7 million reduction in gross profit [13][15] - Full-year EBITDA was $28.3 million, down from $81.4 million in FY24, reflecting a $54.6 million decline in gross profit [15][18] Business Line Data and Key Metrics Changes - In the seed segment, revenues were $63.9 million for the year, a reduction of 34%, attributed to the transition to a royalty-based model [9][12] - Crop protection revenues for the full year were $181.9 million, down 20%, with a strong decline in Argentina offsetting growth in bioprotection in the U.S. and adjuvants in Brazil [8][12] - Crop nutrition revenues were $89.5 million, down 37% year-over-year, driven by lower microbiota fertilizer sales in Argentina [8][12] Market Data and Key Metrics Changes - International sales of core technologies grew, with adjuvant sales in Brazil almost doubling and bioprotection products in the U.S. growing nearly 40% [7] - The company experienced a significant decline in sales in Argentina due to adverse on-farm economics and reduced spending on agricultural inputs [5][6] Company Strategy and Development Direction - The company is focusing on cash generation and improving working capital management, targeting a running rate of five to six months of sales [19][20] - Cost structure adjustments are being accelerated, with targeted operating expense savings of around 10%-12% [19][20] - The company aims to scale up biological initiatives and support key partners in Latin America while onboarding new partnerships in the U.S. and Australia [21][20] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges faced in fiscal 2025, primarily due to macroeconomic shifts in Argentina and a lack of inventory incentives for clients [4][5] - The company expects to improve EBITDA margins and progress towards a more robust balance sheet with a normalized agricultural input market in Argentina and continued growth in the U.S. and Brazil [20][21] - Management emphasized the importance of cash generation and profitability expansion over top-line growth in the current environment [25][26] Other Important Information - Total financial debt stood at $255.5 million, slightly lower than the previous year, with cash and equivalents totaling $34.6 million [17][18] - The company is working closely with creditors to comply with financial obligations and manage upcoming debt maturities [20] Q&A Session Summary Question: What metrics should be focused on in the next six to nine months? - Management indicated that cash generation and profitability expansion will be key metrics, with less emphasis on top-line growth under current circumstances [25][26] Question: Can you elaborate on cost savings initiatives? - Management expects to achieve quarterly savings of $3 million-$3.5 million through workforce streamlining and right-sizing capacities [29][31] Question: What was the gross profit from the Syngenta agreement in FY2025? - The gross profit from the Syngenta agreement for FY2025 was approximately $18 million, down from $16 million in the previous year [35][37] Question: What efforts have been made regarding the HB4 product? - Management highlighted a key agreement in soybeans to reposition HB4 technology, which is expected to generate revenues in the upcoming fiscal year [43][44] Question: What is the current state of inventories in the channel? - Management noted that inventory levels in Argentina have been almost depleted, indicating a potential recovery in sales [62][63]

Financial Data and Key Metrics Changes - Total revenues for the quarter were $60.6 million, down from $84 million in the same period last year, primarily due to the absence of a significant accrual from Syngenta's initial down payment [9][10] - Gross profit decreased to $24 million from $42.6 million year-over-year, with gross margin declining from 51% to 39% due to the previous year's accrual effect [14][15] - Adjusted EBITDA for the quarter was $9 million, down from $21.1 million last year, reflecting the impact of the Syngenta down payment accrual [17][18] - Cash from operating activities improved significantly to $23.3 million, a $40.7 million increase compared to the prior year's cash requirement of $17 million [20][21] - Total debt decreased by $13 million, leading to a leverage ratio of 4.1 at the end of the quarter [23] Business Line Data and Key Metrics Changes - Crop Protection revenues decreased due to lower sales of non-core products in Argentina, partially offset by higher sales of bioprotection solutions [14] - Integrated Products revenues increased by 26%, driven by accelerated sales of HB4 grain from existing inventory [14] - Inoculant sales showed underlying operational growth, slightly offset by seasonal effects on fertilizers [14] Market Data and Key Metrics Changes - The Argentine market experienced reduced commercial activity, with purchasing behavior becoming more aligned with the agronomic calendar rather than speculative patterns [10][11] - The U.S. and Mexico markets showed good growth, indicating early signs of recovery, while Brazil remained in a low season with positive sentiment due to improved soybean prices [12][13] - Overall, the performance in Argentina was not indicative of market status, with expectations for better conditions in the upcoming summer crop season [12][13] Company Strategy and Development Direction - The company is transitioning to a more sustainable agricultural model, focusing on cash flow performance and working capital efficiency [6][20] - The long-awaited EPA approval of Rhinotech allows the company to offer a full suite of biological solutions for pest control and plant health [6] - The company aims to reduce reliance on the Argentine market, targeting growth in Brazil, the U.S., and Europe [70] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism about the Argentine market, noting improved macroeconomic conditions and stable farmer sentiment [51][52] - The company anticipates a healthy winter crop season in Argentina, with expectations for a stronger summer crop season [52][53] - Management highlighted the importance of maintaining operational excellence and leveraging technology platforms for future growth [60][70] Other Important Information - The company has implemented a significant reduction in payroll and structural costs, resulting in annualized savings of approximately $5 million [28] - The Rhinotech platform is positioned for a prelaunch year in 2025, with registrations ongoing in key markets [30][31] Q&A Session Summary Question: Inquiry about cash advancement and working capital unwind - Management indicated an expected additional $10 million from the transition to a lighter model with HB4, aiming for a return to historical net working capital levels of four to four and a half months of sales [44][45] Question: Sentiment in Argentina and macroeconomic conditions - Management noted that sentiment in Argentina is slowly building up, with stable macroeconomic conditions leading to normalized purchasing behavior [50][51] Question: Non-operating income payment details - The $7.5 million non-operating income payment was primarily non-cash, involving an exchange of IP and intangible assets [65] Question: Field trial results for Neovil product - Management confirmed ongoing replicated third-party field trials for Neovil, with positive feedback from strategic and channel partners [94] Question: Interest in HB4 traits from seed companies - Management confirmed ongoing collaboration with public and private institutions for HB4 wheat in the U.S., with a focus on Latin America for HB4 soybeans [97][98]